Wang, Z., et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer 147(2020) 259-268.
Xu, J., et al. Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr 3115).
Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258).
Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era. Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA
Szabo, P. M., et al. Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL.
Download pdf 606KB
View External Link
Luke J., et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Poster session presented at: ESMO 2018 Congress. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288
Hendriks, L. E., et al. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Translational Lung Cancer Research 2018: 7(6):647-660
Aggen, D. H., et al. Biomarkers for immunotherapy in bladder cancer: a moving target. Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1
Foy JP., et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017 Aug 1; 28(8):1934
PMID: 28460011
Knudsen E., et al. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunological Markers. Clin Cancer Res. 2017 Aug 1;23(15):4429
PMID: 28348045
Aggen, D., et al. Biomarkers for immunotherapy in bladder cancer: a moving target. 2017 Journal for ImmunoTherapy of Cancer 5:94
Aggen, D. H., and Drake, C. G. Biomarkers for immunotherapy in bladder cancer: a moving target. Journal for ImmunoTherapy of Cancer (2017) 5:94
Page last updated November 25, 2020